Seattle Children's Hospital
BrainChild's B7-H3 CAR T-Cell Therapy Will Advance to Registrational Phase II Trial in Late 2025
The treatment for aggressive pediatric brain tumors received breakthrough therapy designation from the FDA.
In Brief This Week: MD Anderson, Genascence, Seattle Children's Hospital, Abeona, Mount Sinai
News items for the week of Nov. 11, 2024.
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that patients outside of cancer may not accept.
Seattle Children's to Kick off CAR T-Cell Clinical Trial for Pediatric Lupus Patients This Summer
Premium
The autologous cell therapy, developed by Seattle Children's Therapeutics group, has previously been tested in cancer indications.
Contrasting the experience of three young patients, researchers suggested that a germline ATM mutation may be linked to poor radiation therapy outcomes.
Dec 19, 2023
May 25, 2022